Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide

Neurologist

Volumn 3, Issue 3, 1997, Pages 178-185

  Weinstock Guttman, B ^a   Kinkel, R P ^a   Cohen, J A ^a   Ransohoff, R M ^a   Schwetz, K ^a   Gogol, D ^a   Namey, M ^a   Rudick, R A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cyclophosphamide; Fulminant disease course; Immunosuppression; Multiple sclerosis

Indexed keywords

EID: 0001430776     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-199705000-00005     Document Type: Article

References (25)

1. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppression in progressive multiple sclerosis: A randomized, three-arm study of high dose cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-80.
2. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910-8.
3. Goodkin DE, Plecner S, Palmer-Saxerud J, Teetzen M, Hertsgaard D, et al. Cyclophosphamide in chronic progressive multiple sclerosis: Maintenance vs. nonmaintenance therapy. Arch Neurol 1987;44:823-7.
4. Likosky WH, Fireman B, Elmore R, Eno G, Gale K, Goode GB, et al. Intense immunosuppression in chronic progressive multiple sclerosis: The Kaiser study. J Neurol Neurosurg Psychiatry 1991;54:1055-60.
5. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441-6.
6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996;46:907-11.
7. Aimard G, Girard P-F, Raveau J. Sclerose en plaques et processus d'auto-immunisation: Traitement par les antimitotiques. Lyon Med 1966;215:345-52.
8. Hommes OR, Lamers KJB, Reekers P. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 1980;223:177-90.
9. Gonsette RE, Demonty L, Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. J Neurol 1977;214:173-81.
10. Trouillas P, Neuschwander Ph, Nighoghossian N, Adeleine P, Tremisi P. Immunosuppression intensive dans le sclerose en plaques progressive. Etude ouverte comparant trois groupes: Cyclophosphamide, cyclopohosphamide-plasmapheresis et temoins resultats a trois ans. Rev Neurol (Paris) 1989;145:369-77.
11. Myers LW, Fahey JL, Dewey JM, Mickey MR, Frane MV, Ellison GW. Cyclophosphamide puises in chronic progressive multiple sclerosis. A preliminary clinical trial. Arch Neurol 1987;44:828-32.
12. Noseworthy JH, Ebers GC, Roberts R. Cyclophosphamide and MS. Neurology 1994;44;579.
13. Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Ann Neurol 1990;27:591-605.
14. Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop1 in chronic progressive multiple sclerosis. Neurology 1991;41:533-9.
15. Ellison GW, Myers LW, Leake BD, Mickey MR, Dershin KE, Syndulko K, et al. Design strategies in multiple sclerosis clinical trials. Ann Neurol 1994;36(Suppl):S108-S112.
16. Weinshenker BG, Baskerville J, Ebers GC. Meta-analysis of the placebo treated groups in clinical trials of progressive MS. Neurology 1996;46:1613-9.
17. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 1989; 112:133-46.
18. Hafler DA, Orav J, Gertz R, Stazzone L, Weiner HL. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol 1991;32:149-58.
19. Mickey MR, Ellison GW, Fahey JL, Moody DJ, Lawrence WM. Correlation of clinical and immunologic states in multiple sclerosis. Arch Neurol 1987;44:371-5.
20. Lamers K, Uitdehaag BM, Hommes OR, Doesburg W, Wevers RA, Geel WJA. The short term-effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg. Psychiatry 1988;51:1334-7.
21. Smith DR, Balachov KE, Hafler DA, Khoury SJ, Weiner HL. Pulse intravenous cyclophosphamide therapy induces a shift from a Th1-to a Th2-Type cytokine profile in multiple sclerosis patients [abstract]. Neurology 1995;45:A234.
22. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993;43:1100-4.
23. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40.
24. The IFND Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
25. Mackin GA, Dawson DM, Hafler DA, Weiner HL. Treatment of Multiple Sclerosis with cyclophosphamide. In: Rudick RA, Goodkin D, editors. Treatment of multiple sclerosis: Trial design, results and future perspectives. London: Springer-Verlag, 1992:199-216.